Trial · NCT01562132
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Alive at 12 Weeks | 12 weeks | |
| Secondary | Number of Participants Alive at 2 Weeks | 2 weeks | |
| Secondary | Survival at 24 Weeks | 24 weeks | |
| Secondary | Number of Individuals Who Develop Cryptococcal Meningitis | 24 weeks | Clinical meningitis AND at least one of the following: cryptococcal antigen in the cerebrospinal fluid (CSF), cryptococcal organisms on India Ink stain, or fungal culture of CSF. Clinical meningitis will be defined as: * fever\>39.0°C, AND * severe headache, AND At least one of the following: * meningismus, * photophobia, * new onset seizure, * focal neurological deficit localizable to the central nervous system * papilledema * confusion, delirium, or decreased level of consciousness. |
| Secondary | Number of Individuals Who Develop Immune Reconstitution Inflammatory Syndrome Due to Cryptococcus | 24 weeks | Individuals who develop clinical meningitis without evidence of fungal, bacterial, or parasitic (e.g. malaria) organisms in the cerebrospinal fluid. Clinical meningitis will be defined as: * fever\>39.0°C, AND * severe headache, AND * At least one of the following: * meningismus, * photophobia, * new onset seizure, * focal neurological deficit localizable to the central nervous system * papilledema * confusion, delirium, or decreased level of consciousness. |
| Secondary | Achieve Targeted Recruitment, Retention and Adherence Rates | 24 weeks | |
| Secondary | Proportion of Individuals Requiring Treatment Discontinuation | 4 weeks | |
| Secondary | Proportion of Individuals Requiring Dose Reduction | 24 weeks | |
| Secondary | Number of Individuals With Treatment Related Adverse Events | 24 weeks | |
| Secondary | Number of Individuals With Treatment Related Serious Adverse Events | 24 weeks | |
| Secondary | Cryptococcal Meningitis-free Survival at 24 Weeks | 24 weeks | Clinical meningitis AND at least one of the following: cryptococcal antigen in the cerebrospinal fluid (CSF), cryptococcal organisms on India Ink stain, or fungal culture of CSF. Clinical meningitis will be defined as: * fever\>39.0°C, AND * severe headache, AND At least one of the following: * meningismus, * photophobia, * new onset seizure, * focal neurological deficit localizable to the central nervous system * papilledema * confusion, delirium, or decreased level of consciousness. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01562132/registered